Organ-on-a-Chip Portfolio

The Challenge

Traditional 2D cell cultures and animal models frequently fail to predict human-specific renal toxicity, contributing to the 90% failure rate of new drug compounds in clinical trials.

The Impact

By utilizing a Kidney-on-a-Chip platform that replicates physiological fluid shear stress and active tubular transport mechanisms, researchers successfully identified cellular injury and transporter-mediated nephrotoxicity caused by specific drug candidates before human trials. This approach achieved over 90% correlation with actual human clinical outcomes, allowing teams to filter out high-risk compounds early and save millions in R&D costs.

The Challenge

Assessing oral bioavailability and systemic first-pass metabolism requires understanding how the intestinal barrier and the liver interact dynamically—something isolated cell assays cannot replicate.

The Impact

Using an interconnected Gut-Liver-on-a-Chip system, a pharmaceutical research team successfully simulated oral drug absorption in the intestine followed by real-time hepatic metabolism. The platform monitored continuous effluent samples over extended periods, mapping multi-organ drug interactions with a 3.5-fold higher accuracy than standard static co-cultures, shortening the preclinical screening timeline by nearly 4 weeks.

The Challenge

Evaluating pulmonary inflammation and aerosolized drug delivery demands a model that mimics rhythmic breathing mechanics and alveolar-capillary interface stretching.

The Impact

Deployed in respiratory infection and toxicology studies, a Lung-on-a-Chip device integrated with flexible porous membranes subjected human alveolar cells to continuous mechanical stretch (mimicking 10–12 breaths per minute). The platform successfully quantified barrier integrity changes (via TEER measurements) and cytokine responses to airborne pathogens, yielding human-relevant data that conventional mouse models failed to capture.